Cryo-processed leukapheresis using an automated closed system: a high-quality starting material for autologous and allogeneic CAR-T cell therapy manufacturing

CAR-T manufacturing relies on high-quality leukapheresis starting material, but manual cryopreservation introduces variability that can impact product consistency. This poster presents data evaluating the IntegriCell™ automated closed cryoprocess (ACP), designed to standardize leukapheresis cryopreservation while preserving cell viability and phenotype. The ACP workflow supports reproducible, cGMP-compliant processing for autologous and allogeneic CAR-T applications. This video presentation, accompanied by a poster summary, highlights how cryo-processed leukapheresis performed in an automated closed system can reliably generate high-quality starting material that supports robust, scalable manufacturing of CAR-T cell therapies. NEW INTERACTIVE FORMAT Listen to our expert speaker. Watch the video. Read the summary. Focus in on the data. Download the PDF. It has never been easier to quickly access the information you want. All in one place—at the click of a button.

Please enter your email to access content Read now